EVerZom raises 10 million euros to push exosome therapy into clinic

French biotech EVerZom has raised 10 million euros ($10.9 million) to launch its first clinical trial and expand its exosome platform into new areas such as liver and skin disease. The financing round attracted support from Capital Grand Est, the European Innovation Council Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices.

The funds will back a 2026 trial of EVerGel, the company’s lead program for Crohn’s perianal fistula. The disease is a major unmet need following Takeda’s withdrawal of stem cell treatment Alofisel from the EU market in 2024 after a confirmatory trial failed. Preclinical work with EVerGel showed nearly 90% healing in animals, compared to 13% with controls.

Exosomes are nanosized biological particles that naturally facilitate intercellular communication. EVerZom has built a proprietary platform covering cell sourcing, exosome generation, purification and formulation, supported by patent protections. It has already achieved GMP-grade production in a 10-liter bioreactor and now aims to scale to 50 liters, with help from a 3 million euro France 2030 grant.